Abstract
Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Current Drug Targets
Title: “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”
Volume: 11 Issue: 2
Author(s): Walter Reinisch
Affiliation:
Abstract: Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Export Options
About this article
Cite this article as:
Reinisch Walter, “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309894
DOI https://dx.doi.org/10.2174/138945010790309894 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parkinsons Disease and Obsessive-Compulsive Phenomena: A Systematic Review
Current Psychiatry Reviews The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?
Current Pharmacogenomics Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Anti-Angiogenic Therapy in Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Novel Aceclofenac Cocrystals with l-Cystine: Virtual Coformer Screening, Mechanochemical Synthesis, and Physicochemical Investigations
Current Drug Delivery Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates
New Emirates Medical Journal High Podophyllotoxin Producing Hairy Root Line of Linum Album: Influence of Carbohydrates, Temperature and Photoperiod
Current Biotechnology Analysis of Nucleic Acids and Proteins in Capillary Electrophoresis and Microchip Capillary Electrophoresis Using Polymers as Additives of the Background Electrolytes
Current Analytical Chemistry Wealth of Opportunity - The C1 Domain as a Target for Drug Development
Current Drug Targets Drugs Made of RNA: Development and Application of Engineered RNAs for Gene Therapy
Mini-Reviews in Medicinal Chemistry Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment
Current Drug Targets Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Current Pharmaceutical Design Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry